MedTrace Logo

Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System

NCT05420558 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-07-17

No results posted yet for this study

Summary

The purpose of this single center prospective study is to assess the value of FAPI PET imaging in predicting early postoperative recurrence of malignant tumor of digestive system and to evaluate the diagnostic performance of FAPI PET/CT in the detection of primary tumor and metastatic lesions.

Conditions

Interventions

DIAGNOSTIC_TEST

Fibroblast activation protein inhibitor PET/CT imaging

All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging

Sponsors & Collaborators

  • Zhongnan Hospital

    lead OTHER

Principal Investigators

  • Chongjiao Li, MD, PhD · Wuhan University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-23
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05420558 on ClinicalTrials.gov